These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26021524)

  • 1. Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review.
    Rijks EB; Bongers BC; Vlemmix MJ; Boot AM; van Dijk AT; Sakkers RJ; van Brussel M
    Horm Res Paediatr; 2015; 84(1):26-42. PubMed ID: 26021524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.
    Ying ZM; Hu B; Yan SG
    Orthop Surg; 2020 Aug; 12(4):1293-1303. PubMed ID: 32589343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
    Dimeglio LA; Ford L; McClintock C; Peacock M
    J Pediatr Endocrinol Metab; 2005 Jan; 18(1):43-53. PubMed ID: 15679068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Ward LM; Rauch F; Whyte MP; D'Astous J; Gates PE; Grogan D; Lester EL; McCall RE; Pressly TA; Sanders JO; Smith PA; Steiner RD; Sullivan E; Tyerman G; Smith-Wright DL; Verbruggen N; Heyden N; Lombardi A; Glorieux FH
    J Clin Endocrinol Metab; 2011 Feb; 96(2):355-64. PubMed ID: 21106710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.
    Hald JD; Evangelou E; Langdahl BL; Ralston SH
    J Bone Miner Res; 2015 May; 30(5):929-33. PubMed ID: 25407702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta.
    Vuorimies I; Mäyränpää MK; Valta H; Kröger H; Toiviainen-Salo S; Mäkitie O
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1333-1339. PubMed ID: 28323993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
    J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis.
    Shi CG; Zhang Y; Yuan W
    Am J Ther; 2016; 23(3):e894-904. PubMed ID: 25844482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent Proximal Femur Fractures in a Teenager With Osteogenesis Imperfecta on Continuous Bisphosphonate Therapy: Are We Overtreating?
    Vasanwala RF; Sanghrajka A; Bishop NJ; Högler W
    J Bone Miner Res; 2016 Jul; 31(7):1449-54. PubMed ID: 26845496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
    J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment.
    Vuorimies I; Arponen H; Valta H; Tiesalo O; Ekholm M; Ranta H; Evälahti M; Mäkitie O; Waltimo-Sirén J
    Bone; 2017 Jan; 94():29-33. PubMed ID: 27725317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.